National Symposium 2014

101 - The Changing Faces of Nephropathic Cystinosis: Clinical Challenges and Emerging Opportunities

Apr 13, 2014 11:45am ‐ Apr 13, 2014 1:00pm

Standard: $20.00
Members: $0.00

Description

Contact hours available until 4/16/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Speaker, Faculty, Planners and Authors Conflict of Interest Disclosure:

Planning disclosures:
Barbara Monaghan discloses that she receives other financial/material support as owner of Cornerstone Medical Communications.
Patricia Wasserman discloses that she receives other financial/material support as owner of Cornerstone Medical Communications.

Speaker disclosures:
Ewa Elenberg discloses that she has received grant/research support from Raptor Therapeutics Inc., that she is a consultant/speaker’s bureau member for Raptor Pharmaceuticals, and that she is on the advisory board for Raptor Pharmaceuticals.
Paul Grimm receives research/grant support as Stanford primary investigator in studies of cystinosis and Procysbi in patients. Dr. Grimm also discloses that he is a member of the advisory board to Raptor Pharmaceuticals.
Ivette Jones discloses that she is is a member of the Raptor Pharmaceuticals Speaker's Bureau.

Planning Committee:
• Annette Hood discloses that she is a member of the Amgen speakers’ bureau.
• Denise Murcek discloses other financial/material support as an employee of the VA Medical Center.
• Elizabeth St. John discloses other financial/material support as an employee of Fresenius Medical Care.
• Kyra Trappett discloses other financial/material support as an employee of DaVita.

Commercial Support and Sponsorship:
Supported by an educational grant from Raptor Pharmaceuticals

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

Objectives:
• Delineate pathological features of cystinosis.
• Identify infants and children at increased risk for the disease.
• Recognize early signs and symptoms as well as clinical manifestations of complications in young adults.

Speaker(s):

You must be logged in and own this session in order to post comments.